Nurix Therapeutics, Inc. — Form 10-Q
Filed October 13, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Nurix Therapeutics and Roche (including Genentech and F. Hoffmann-La Roche Ltd) entered into a comprehensive license and collaboration agreement effective June 8, 2026. Roche receives an exclusive, worldwide license to Nurix's BTK degrader technology (Bexobrutideg/NX-5948 and derivatives) for development, manufacturing, and commercialization in all indications. Financial consideration includes: $700M upfront payment, up to $160M in oncology development milestones, up to $280M in oncology approval milestones, up to $130M in [redacted field] development milestones, up to $210M in oncology launch milestones, up to $90M in [redacted field] launch milestones, up to $710M in annual net sales milestones, tiered royalties (rates redacted) in Roche Territory, and 50/50 profit/loss sharing in US (Joint Territory). Nurix retains co-development/co-commercialization rights in US and option rights to additional BTK degraders.
Why this rating
Large transaction ($700M upfront alone ~87% of Nurix market cap) providing substantial near-term capital and milestone potential (~$1.6B total), transforming Nurix's financial position and de-risking company via Roche's development/commercialization resources.
Tradability signal
NO TRADE
No trade: positive news with only -0.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.51% over 4 hrs, n=187). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $21.75 | +10 min · unknown $22.18 ▲ 1.98% | +30 min · unknown $22.02 ▲ 1.26% | +1 hr · unknown $22.11 ▲ 1.63% | +4 hrs · unknown $22.80 ▲ 4.85% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.